Overview

A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The study drug LY2393910 is being evaluated as a possible treatment for diabetes. The primary purpose of a patient's participation in this study is to help answer the following research question(s), and not to provide treatment for diabetes: - The safety of LY2393910 and any side effects that might be associated with it following 2 weeks of doses - How long it takes the body to absorb and remove LY2393910 following dosing over 2 weeks - How daily dosing of LY2393910 affects blood levels of sugar (glucose), insulin and other naturally occurring substances in your body - How daily dosing of LY2393910 affects the cells that produce insulin - Any differences in the above between LY2393910 taken as daily doses in the morning or in the evening
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company